76 related articles for article (PubMed ID: 11598415)
1. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.
Wang SS; Zimmermann M; Zhang H; Lin TY; Malfatti M; Haack K; Turteltaub KW; Cimino GD; de Vere White R; Pan CX; Henderson PT
Int J Cancer; 2017 Aug; 141(3):604-613. PubMed ID: 28437852
[TBL] [Abstract][Full Text] [Related]
2. FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment.
Shimoyama S; Okada K; Kimura T; Morohashi Y; Nakayama S; Kemmochi S; Makita-Suzuki K; Matulonis UA; Mori M
Mol Cancer Ther; 2023 Dec; 22(12):1454-1464. PubMed ID: 37683276
[TBL] [Abstract][Full Text] [Related]
3. Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.
Domvri K; Zarogoulidis K; Zogas N; Zarogoulidis P; Petanidis S; Porpodis K; Kioseoglou E; Hohenforst-Schmidt W
J Cancer; 2017; 8(18):3648-3656. PubMed ID: 29151951
[No Abstract] [Full Text] [Related]
4. Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts.
Gürgen D; Conrad T; Becker M; Sebens S; Röcken C; Hoffmann J; Langhammer S
Commun Biol; 2022 Jan; 5(1):59. PubMed ID: 35039644
[TBL] [Abstract][Full Text] [Related]
5. A review of topotecan in combination chemotherapy for advanced cervical cancer.
Robati M; Holtz D; Dunton CJ
Ther Clin Risk Manag; 2008 Feb; 4(1):213-8. PubMed ID: 18728710
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of Chrysin and Luteolin with Cisplatin and Topotecan Exhibits a Variable Therapeutic Value in Human Cancer Cells, HeLa.
Raina R; Hussain A; Almutary AG; Haque S; Raza T; D'Souza AC; Subramani S; Sajeevan A
ACS Omega; 2023 Nov; 8(44):41204-41213. PubMed ID: 37970041
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment.
Li Q; Chen S; Wang X; Cai J; Huang H; Tang S; He D
Curr Drug Targets; 2024 Apr; ():. PubMed ID: 38591210
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
Gryder BE; Rood MK; Johnson KA; Patil V; Raftery ED; Yao LP; Rice M; Azizi B; Doyle DF; Oyelere AK
J Med Chem; 2013 Jul; 56(14):5782-96. PubMed ID: 23786452
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies.
Burris HA; Infante JR; Jewell RC; Spigel DR; Greco FA; Thompson DS; Jones SF
Oncologist; 2010; 15(9):954-60. PubMed ID: 20798192
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.
Beldner MA; Sherman CA; Green MR; Garrett-Mayer E; Chaudhary U; Meyer ML; Kraft AS; Montero AJ
BMC Cancer; 2007 Dec; 7():231. PubMed ID: 18096059
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Nagourney RA; Sommers BL; Harper SM; Radecki S; Evans SS
Br J Cancer; 2003 Nov; 89(9):1789-95. PubMed ID: 14583785
[TBL] [Abstract][Full Text] [Related]
12. Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine.
Stupp R; Bodmer A; Duvoisin B; Bauer J; Perey L; Bakr M; Ketterer N; Leyvraz S
Oncology; 2001; 61 Suppl 1():35-41. PubMed ID: 11598413
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer.
Eckardt JR
Oncology; 2001; 61 Suppl 1():30-4. PubMed ID: 11598412
[TBL] [Abstract][Full Text] [Related]
14. Update on the role of topotecan in the treatment of non-small cell lung cancer.
Stewart DJ
Oncologist; 2004; 9 Suppl 6():43-52. PubMed ID: 15616149
[TBL] [Abstract][Full Text] [Related]
15. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Chiappori AA; Ellis PM; Hamm JT; Bitran JD; Eiseman I; Lovalvo J; Burnett D; Olson S; Lenehan P; Zinner RG
J Thorac Oncol; 2006 Nov; 1(9):1010-9. PubMed ID: 17409987
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.
Rossi A; Di Maio M; Chiodini P; Rudd RM; Okamoto H; Skarlos DV; Früh M; Qian W; Tamura T; Samantas E; Shibata T; Perrone F; Gallo C; Gridelli C; Martelli O; Lee SM
J Clin Oncol; 2012 May; 30(14):1692-8. PubMed ID: 22473169
[TBL] [Abstract][Full Text] [Related]
17. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.
Pujol JL; von Pawel J; Tumolo S; Martoni A; Hearn S; Fields SZ; Ross G
Oncology; 2001; 61 Suppl 1():47-54. PubMed ID: 11598415
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
